Cited by 371Blood Coagulation and Thrombosis MechanismsAdipokines, Inflammation, and Metabolic DiseasesProtease and Inhibitor Mechanisms

The DOI matches its Crossref record; 95 of the 95 references it cites were found in a registry or an index.

Plasminogen activator inhibitor-1, inflammation, obesity, insulin resistance and vascular risk

Open access

Juhan-Vague, I., Alessi, M-C., Mavri, A., Morange, P.E.·2003·Journal of Thrombosis and Haemostasis

DOI 10.1046/j.1538-7836.2003.00279.x

Open this paper in CoChat — free account

Abstract

Elevated plasma plasminogen activator inhibitor-1 (PAI-1) level is a core feature of insulin-resistance syndrome (IRS). Atherothrombotic complications in IRS are partly attributed to impaired fibrinolysis caused by increased plasma PAI-1 levels. Although the etiology of IRS is far from being explained, the clustering of inflammation, adipose tissue accumulation and insulin resistance suggests an etiopathological link. Proinflammatory cytokines might regulate PAI-1 expression in IRS; however, more studies are needed to confirm this complex mechanism in humans. Furthermore, modifying PAI-1 expression by PAI-1 inhibitors provides a new challenge and may reveal the true role of PAI-1 in atherosclerotic and insulin resistance processes.

Integrity signals

Registry

Crossref · 10.1046/j.1538-7836.2003.00279.x

Cites

95 of 95 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Effects of an Angiotensin-Converting–Enzyme Inhibitor, Ramipril, on Cardiovascular Events in High-Risk Patients
(2000) · New England Journal of Medicine · doi:10.1056/nejm200001203420301 · Cited by 8,663
Inflammation in atherosclerosis
Libby, P. (2002) · Nature · doi:10.1038/nature01323 · Cited by 8,315
Adipose Expression of Tumor Necrosis Factor-α: Direct Role in Obesity-Linked Insulin Resistance
Hotamisligil, G. S., Shargill, N. S., & Spiegelman, B. M. (1993) · Science · doi:10.1126/science.7678183 · Cited by 7,518
Prevalence of the Metabolic Syndrome Among US Adults: Findings From the Third National Health and Nutrition Examination Survey
Ford, E. S., Giles, W. H., & Dietz, W. H. (2002) · JAMA · doi:10.1001/jama.287.3.356 · Cited by 6,698
Cardiovascular Morbidity and Mortality Associated With the Metabolic Syndrome
Isomaa, B., Almgren, P., Tuomi, T., Forsén, B., Lahti, K., Nissén, M., Taskinen, M.-R., & Groop, L. (2001) · Diabetes Care · doi:10.2337/diacare.24.4.683 · Cited by 4,760
C-Reactive Protein, Interleukin 6, and Risk of Developing Type 2 Diabetes Mellitus
Pradhan, A. D. (2001) · JAMA · doi:10.1001/jama.286.3.327 · Cited by 4,433
PPAR-γ agonists inhibit production of monocyte inflammatory cytokines
Jiang, C., Ting, A. T., & Seed, B. (1998) · Nature · doi:10.1038/34184 · Cited by 2,899
IRS-1-Mediated Inhibition of Insulin Receptor Tyrosine Kinase Activity in TNF-α- and Obesity-Induced Insulin Resistance
Hotamisligil, G. S., Peraldi, P., Budavari, A., Ellis, R., White, M. F., & Spiegelman, B. M. (1996) · Science · doi:10.1126/science.271.5249.665 · Cited by 2,630
C-Reactive Protein in Healthy Subjects: Associations With Obesity, Insulin Resistance, and Endothelial Dysfunction: A Potential Role for Cytokines Originating From Adipose Tissue?
Yudkin, J. S., Stehouwer, C. D. A., Emeis, J. J., & Coppack, S. W. (1999) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.19.4.972 · Cited by 2,465
Chronic Subclinical Inflammation as Part of the Insulin Resistance Syndrome
Festa, A., D’Agostino, R., Howard, G., Mykkänen, L., Tracy, R. P., & Haffner, S. M. (2000) · Circulation · doi:10.1161/01.cir.102.1.42 · Cited by 2,366

Show all 95 references

Research works printed but not linked: 1

Mohamed-Ali, 1997, Human subcutaneous adipose tissue secretes interleukin-6 but not tumour necrosis factor-αin vivo, J Clin Endocrinol Metab, 82, 4196

Sorted by citations

Items 201–300 of 369

Novel insights and an updated review of metabolic syndrome in immune-mediated organ transplant rejection
Tao, Z., Luo, Z., Zou, Z., Ye, W., Hao, Y., Li, X., Zheng, K., Wu, J., Xia, J., Zhao, Y., et al. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1580369 · Cited by 14
“Moreover, an increase in FFAs leads to a decrease in brachial artery dilatation function and hypertension in MetS patients (11); additionally, insulin resistance in MetS patients increases blood viscosity (12).”
The Nε-(carboxymethyl)lysine–RAGE axis: putative implications for the pathogenesis of obesity-related complications
Gaens, K. H. J., Stehouwer, C. D. A., & Schalkwijk, C. G. (2010) · Expert Review of Endocrinology & Metabolism · doi:10.1586/eem.10.68 · Cited by 14
Long-term effects of pioglitazone versus gliclazide on hepatic and humoral coagulation factors in patients with type 2 diabetes
Perriello, G., Pampanelli, S., Brunetti, P., Pietro, C. D., & Mariz, S. (2007) · Diabetes and Vascular Disease Research · doi:10.3132/dvdr.2007.044 · Cited by 14
Plasminogen activator inhibitor type‐1 is an independent marker of metabolic disorders in young adults born small for gestational age
Meas, T., Deghmoun, S., Chevenne, D., Gaborit, B., Alessi, M., & Lévy‐Marchal, C. (2010) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2010.04037.x · Cited by 13
Self-citation
African American Women, Metabolic Syndrome, and National Cholesterol Education Program Criteria
Appel, S. J., Floyd, N. A., Giger, J. N., Weaver, M. T., Luo, H., Hannah, T., & Ovalle, F. (2005) · Nursing Research · doi:10.1097/00006199-200509000-00008 · Cited by 13
The metabolic syndrome: A vascular perspective
Tamsma, J. T., Jazet, I. M., Beishuizen, E. D., Fogteloo, A. J., Meinders, A. E., & Huisman, M. V. (2005) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2005.01.011 · Cited by 13
The metabolic syndrome: linking oxidative stress and inflammation to obesity, type 2 diabetes, and the syndrome
Dandona, P., Ghanim, H., Mohanty, P., & Chaudhuri, A. (2006) · Drug Development Research · doi:10.1002/ddr.20137 · Cited by 12
“…in proinflammatory states, such as the metabolic syndrome obesity and type 2 diabetes and polycystic ovary syndrome (PCOS), with an increase in the risk of atherosclerosis and its complications, such as acute myocardial infarction and stroke [Gonzalez et al., 1999; Juhan-Vague et al., 2003].”
Background
A metabolic syndrome independent association between overweight, fibrinolysis impairment and low-grade inflammation in young women with venous thromboembolism
Salobir, B., & Šabović, M. (2006) · Blood Coagulation & Fibrinolysis · doi:10.1097/01.mbc.0000245298.64644.0a · Cited by 12
Metabolic syndrome among Puerto Ricans and other Hispanic populations.
Marcial, J. M., Altieri, P. I., Banchs, H. L., Escobales, N., & Crespo, M. J. (2011) · PubMed · Cited by 12
Plasma Plasminogen Activator Inhibitor-1 Levels and Nonalcoholic Fatty Liver in Individuals With Features of Metabolic Syndrome
Larrañaga, G. F. D., Wingeyer, S. D. P., Graffigna, M. N., Belli, S., Bendezú, K., Alvarez, S., Levalle, O. A., & Fainboim, H. A. (2007) · Clinical and Applied Thrombosis/Hemostasis · doi:10.1177/1076029607304094 · Cited by 12
“9) Alkaline phosphatase (U/L) 195 (160-231) Alanine aminotransferase (IU/L) 23 (18-32) Aspartate aminotransferase (IU/L) 30 (16-47) γ-Glutamyltransferase (U/L) 35 (19-52) PAI-1 (ng/mL) 20.”
Obesity enhances the induction of plasminogen activator inhibitor‐1 by restraint stress: a possible mechanism of stress‐induced renal fibrin deposition in obese mice
Yamamoto, K., Kojima, T., ADACHI, T., HAYASHI, M., Matsushita, T., Takamatsu, J., Loskutoff, D. J., & Saito, H. (2005) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2005.01399.x · Cited by 12
Gene expression of different adipose tissues of severely obese women with or without a dysmetabolic profile
Mauriège, P., Joanisse, D. R., Caspar‐Bauguil, S., Cartier, A., Lemieux, I., Bergeron, J., Biron, S., Marceau, P., & Richard, D. (2015) · Journal of Physiology and Biochemistry · doi:10.1007/s13105-015-0436-6 · Cited by 11
“The increased obesity-related CHD risk has previously been related to a higher AT express ion and product ion of angiotensinogen and plasminogen activator inhibitor-1 (PAI-1) [17, 20].”
Background
Probing nanosecond motions of plasminogen activator inhibitor-1 by time-resolved fluorescence anisotropy
Ko, C. W., Wei, Z., Marsh, R. J., Armoogum, D. A., Nicolaou, N., Bain, A. J., Zhou, A., & Ying, L. (2009) · Molecular BioSystems · doi:10.1039/b901691k · Cited by 11
The 6th Annual World Congress on the Insulin Resistance Syndrome
Bloomgarden, Z. T. (2009) · Diabetes Care · doi:10.2337/dc09-zb09 · Cited by 11
Interrelationships of factor VII activity and plasma leptin with insulin resistance in coronary heart disease
Karatela, R. A., & Sainani, G. S. (2009) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2009.08.043 · Cited by 11
Predictive cut-off values for the triglyceride-to-high-density lipoprotein cholesterol ratio to predict metabolic syndrome in the middle-aged Korean population
Kim, J. Y., Lee, T., & Chung, T. (2024) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2024.01.023 · Cited by 10
Metabolic Syndrome, Obesity Paradox and Testosterone Level
Emanuele, V. (2015) · Endocrinology & Metabolic Syndrome · doi:10.4172/2161-1017.1000172 · Cited by 10
Racial disparities in reasons for mortality following bariatric surgery
Edwards, M. A., Muraleedharan, D., & Spaulding, A. (2022) · Journal of Racial and Ethnic Health Disparities · doi:10.1007/s40615-022-01242-5 · Cited by 10
“PAI-1 decreases the fibrinolytic activity by blocking the conversion of plasminogen to plasmin, thus creating a hypercoagulable state and increased risk for VTE [34, 35].”
Background
Effect of daily ingestion of Bifidobacterium and dietary fiber on vascular endothelial function: a randomized, double-blind, placebo-controlled, parallel-group comparison study
Azuma, N., Saito, Y., Nishijima, T., Aoki, R., & Nishihira, J. (2023) · Bioscience Biotechnology and Biochemistry · doi:10.1093/bbb/zbad148 · Cited by 10
Cholesterol, Atherosclerosis and Coronary Disease in the UK, 1950–2000, vol. 27.
Reynolds, L., & Em, T. (2006) · UCL Discovery (University College London) · Cited by 10
Correlation of Childhood Obesity and Related Insulin Resistance with Leptin and Retinol Binding Protein 4
Vasanthi, T., Amperayani, S., Babu, R. P., & Uppuluri, R. (2015) · The Indian Journal of Pediatrics · doi:10.1007/s12098-015-1706-6 · Cited by 10
“predictors for T2DM in the future [3].”
Mulberry (Morus albaL.) ethanol extract attenuates lipid metabolic disturbance and adipokine imbalance in high-fat fed rats
Noh, D.-J., & Yoon, G.-A. (2022) · Nutrition Research and Practice · doi:10.4162/nrp.2022.16.6.716 · Cited by 10
“Therefore, when aberrant production of adipokines is persistent, the body is likely to face an inflammatory and prothrombotic milieu, which can contribute to the development of obesity-linked metabolic diseases [5,6,34].”
Background
Injury-induced insulin resistance in adipose tissue
Williams, V. L., Martin, R. E., Franklin, J. L., Hardy, R. W., & Messina, J. L. (2012) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2012.03.146 · Cited by 10
Nicotine exposure suppresses hyperinsulinemia and improves endothelial dysfunction mediators independent of corticosteroids in insulin-resistant oral contraceptive-treated female rats
Michael, O. S., & Olatunji, L. A. (2017) · Drug and Chemical Toxicology · doi:10.1080/01480545.2017.1413109 · Cited by 9
METABOLIC SYNDROME. ETIOLOGY AND PATHOGENESIS
Diemieszczyk, I., Głuszyńska, P., Wojciak, P. A., Ładny, J. R., & Hady, H. R. (2021) · Wiadomości Lekarskie · doi:10.36740/wlek202110126 · Cited by 9
De novo synthesis of diacylglycerol in endothelium may mediate the association between PAI-1 and the insulin resistance syndrome
McCarty, M. F. (2004) · Medical Hypotheses · doi:10.1016/j.mehy.2004.03.038 · Cited by 9
“Plasma levels of PAI-1 are typically elevated in insulin resistance syndrome and diabetes [12,13].”
Background
Hemostatic abnormalities associated with obesity and the metabolic syndrome
Lowe, G. D. O., Rumley, A., & Wannamethee, S. G. (2005) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2005.01301.x · Cited by 9
Kaempferol ameliorates metabolic syndrome by inhibiting inflammation and oxidative stress in high-fat diet-induced obese mice
Shin, S., & Kwon, E. (2024) · Nutrition Research and Practice · doi:10.4162/nrp.2024.18.3.325 · Cited by 8
“In addition, pro-inflammatory cytokines, such as IL-6 and PAI-1, exhibit increased plasma levels in cases of obesity and insulin resistance [46,47].”
Background
Predictors of venous thromboembolism in COVID-19 patients: results of the COVID-19 Brazilian Registry
da Silveira, W. C., Ramos, L. E. F., Silva, R. T., de Paiva, B. B. M., Delfino-Pereira, P., Schwarzbold, A. V., Garbini, A. F., Barreira, B. S. M., de Castro, B. M., Ramos, C. M., et al. (2022) · Internal and Emergency Medicine · doi:10.1007/s11739-022-03002-z · Cited by 8
Erratum to: Correlation of Childhood Obesity and Related Insulin Resistance with Leptin and Retinol Binding Protein 4
Vasanthi, T., Amperayani, S., Babu, R. P., & Uppuluri, R. (2015) · The Indian Journal of Pediatrics · doi:10.1007/s12098-015-1837-9 · Cited by 8
“predictors for T2DM in the future [3].”
Palmitoylethanolamide, adipocytes and obesity-related inflammatory states
Hoareau, L., & Roche, R. (2010) · Drug Discovery Today Disease Mechanisms · doi:10.1016/j.ddmec.2011.01.002 · Cited by 8
Degree of obesity influences the relationship of PAI-1 with body fat distribution and metabolic variables in African women
Barnard, S. A., Pieters, M., Nienaber‐Rousseau, C., & Kruger, H. S. (2016) · Thrombosis Research · doi:10.1016/j.thromres.2016.09.003 · Cited by 7
Contribution Of Sphingolipids To The Pathogenesis Of Obesity
Samad, F. (2007) · Future Lipidology · doi:10.2217/17460875.2.6.625 · Cited by 7
Cocoa flavonoids: A natural approach to regulating metabolic health and combating metabolic syndrome
Dimeji, I. Y., Abass, K. S., Jabba, H. L., Murtala, N., Adeoye, S. W., & Baba, Z. M. (2025) · Food Bioscience · doi:10.1016/j.fbio.2025.107210 · Cited by 6
Molecular Adaptation of Cardiac Remodeling in Metabolic Syndrome: Focus on AMPK, SIRT1 and PGC-1a
Ramadhan, A. Y., & Soetikno, V. (2024) · Molecular and Cellular Biomedical Sciences · doi:10.21705/mcbs.v8i1.367 · Cited by 5
“15,19 Hyperinsulinemia promotes the uptake of free fatty acids in the heart due to the upregulation of cluster of differentiation (CD)36, a fatty acid transporter.”
Background
Relationship between Changes in Plasma Leptin Concentrations and Plasminogen Activator Inhibitor-1 in Obese Prepubertal Children after Nine Months of Treatment
Jiménez, M. V., Martos, R., Morales, R. M., Valle, R., Cañete, M. D., Urbano, M. M., Bermudo, F., & Cañete, R. (2013) · Annals of Nutrition and Metabolism · doi:10.1159/000351597 · Cited by 6
The Role of Insulin Resistance on FGF-21 and Inflammatory Markers in Obese Adolescents Undergoing Multicomponent Long-Term Weight Loss Therapy
Campos, R. M. D. S., Oyama, L. M., Masquio, D. C. L., Vicente, S. E. D. C. F., Corgosinho, F. C., Kravchychyn, A. C. P., Tock, L., Tufik, S., de Mello, M. T., & Dâmaso, A. R. (2017) · European Medical Journal · doi:10.33590/emj/10313484 · Cited by 6
Effects of High Glucose and Ketosis (Acetoacetate, ß-Hydroxybutyrate) on PAI-1 Secretion in Human Umbilical Vascular Endothelial Cells
Velusamy, T., & Jain, S. K. (2010) · Clinical and Applied Thrombosis/Hemostasis · doi:10.1177/1076029610366434 · Cited by 6
“Impaired fibrinolysis due to elevated plasma PAI-1 levels appears to be an independent risk factor for myocardial infarction.(2) Plasma levels of PAI-1 are mediated by the presence of several atherosclerotic risk factors such as hypertriglyceridemia, diabetes, and insulin resistance.”
Background
Insulin Enhancement of Cytokine-Induced Coagulation/Inflammation-Related Gene Transcription in Hepatocytes
Okazaki, M., Iwasaki, Y., He, J., Nishiyama, M., Taguchi, T., Tsugita, M., Taniguchi, Y., Kambayashi, M., & Hashimoto, K. (2008) · Endocrine Journal · doi:10.1507/endocrj.k08e-078 · Cited by 6
Changes in mediators of inflammation and pro-thrombosis after 12 months of dietary modification in adults with metabolic syndrome
Rahamon, S. K., Fabian, U. A., Charles-Davies, M. A., Olaniyi, J. A., Fasanmade, A. A., Akinlade, K. S., Oyewole, O. E., Owolabi, M. O., Adebusuyi, J. R., Hassan, O. O., et al. (2017) · African Health Sciences · doi:10.4314/ahs.v17i2.20 · Cited by 5
Exploring the Therapeutic Potential of Apigenin in Obesity-Associated Fibrinolytic Dysfunction: Insights From an Animal Study
Qadi, H. H., Bendary, M., Almaghrabi, S., Zaher, M., Karami, M. M., Alsehli, A. M., Babateen, O., Arbaeen, A. F., Burzangi, A. S., & Bazuhair, M. A. (2023) · Cureus · doi:10.7759/cureus.40943 · Cited by 6
“The pathogenesis of fibrinolytic dysfunction in obesity is correlated to body mass index (BMI), insulin resistance (IR), oxidative stress, and low-grade inflammation [8,9].”
Background
Third Annual World Congress on the Insulin Resistance Syndrome
Bloomgarden, Z. T. (2006) · Diabetes Care · doi:10.2337/dc06-zb08 · Cited by 5
“Insulin and triglyceride may have direct effects on plasminogen activator inhibitor (PAI)-1 (52).”
Background
Thrombophilia and thrombosis
Obradović, D. (2005) · Medicinski pregled · doi:10.2298/mpns0508368o · Cited by 5
MicroRNAs and Endothelial Dysfunction in Relation to Obesity and Type 2 Diabetes
Karolina, D. S. (2014) · Journal of Molecular and Genetic Medicine · doi:10.4172/1747-0862.s1-011 · Cited by 5
“The ectopic lipid accumulation and excess secretion of pro-inflammatory adipokines such as TNF-α, resistin, PAI-1 and IL-6 dampen insulin action hence increasing insulin resistance, atherogenic dyslipidemia and hyperinsulinemia [49-52].”
Resolving distinct molecular origins for copper effects on PAI-1
Bucci, J. C., McClintock, C. S., Chu, Y., Ware, G. L., McConnell, K. D., Emerson, J. P., & Peterson, C. B. (2017) · JBIC Journal of Biological Inorganic Chemistry · doi:10.1007/s00775-017-1489-5 · Cited by 5
“Removal of PAI-1 results in compromised wound healing and mild bleeding states due to lack of control of the fibrinolytic components [6, 7], At the same time, excessive levels of PAI-1 result in atherosclerosis [8], fibrosis in several tissue types [9], inflammation [10], metabolic syndrome [11], and cancer [12].”
Background
Relationship between serum and tear levels of tissue plasminogen activator and plasminogen activator inhibitor-1 in diabetic retinopathy
Jasmiad, N. B., Ghani, R. B. A., Agarwal, R., Ismail, Z. B., Abdullah, A. A. M., & Idorus, M. Y. (2022) · BMC Ophthalmology · doi:10.1186/s12886-022-02550-4 · Cited by 5
The effects of fibrates on lipid metabolism and inflammation in type 2 diabetes
Chapman, M. J. (2006) · Diabetes and Vascular Disease Research · doi:10.1177/147916410600300103 · Cited by 5
“In addition, elevated levels of plasminogen-activator inhibitor protein-1 (PAI-1) favour development of a prothrombotic state.(13) Given the nature of the atherogenic dyslipidaemia typically associated with type 2 diabetes, the role of lipidmodifying therapy in attenuating diabetes-related macrovascular atheroscleroti…”
Background
Fibrinolysis and diabetic vascular disease: roles of plasminogen activator inhibitor-1 and thrombin-activatable fibrinolysis inhibitor
Aso, Y. (2006) · Future Lipidology · doi:10.2217/17460875.1.4.429 · Cited by 5
“Plasma PAI-1 is also strongly correlated with components of metabolic syndrome such as body mass index, visceral fat, blood pressure, plasma insulin, triglyceride and HDL-C in subjects with metabolic syndrome and Type 2 diabetes [54,55].”
Background
Dysmetabolic Syndrom
Appel, S. J., Giger, J. N., & Floyd, N. A. (2004) · The Nurse Practitioner · doi:10.1097/00006205-200410000-00004 · Cited by 5
“of fibrin or PAI-1, has been associated with inflammation, elevated CRP, as well as with myocardial infarction, stroke, and other forms of vascular injury.(14,28,56,57) Lifestyle factors that result in high levels of physical activity or antioxidants, such as diets rich in alpha-tocopherol (i.”
Background
Comparison of the effect of consuming the prepared cakes with acorn flour and wheat flour following a hypocaloric diet on serum levels of leptin, endothelin, inflammatory factors, and oxidative stress parameters in obese and overweight patients with metabolic syndrome: A double‐blind clinical trial
Sadeghi‐Dehsahraei, H., Babajafari, S., Ashrafi, M., & Sartang, M. M. (2024) · Food Science & Nutrition · doi:10.1002/fsn3.4393 · Cited by 4
Liver steatosis is positively associated with plasminogen activator inhibitor-1 in apparently healthy individuals with overweight and obesity: A FibroScan-Based Cross-Sectional study
Lisco, G., Guido, D., Cerabino, N., Chito, M. D., Donvito, R., Bonfiglio, C., Shahini, E., Zappimbulso, M., Randazzo, C., Barletta, D., et al. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-06464-9 · Cited by 4
“…systemic inflammation, and overproduction of pro-inflammatory cytokines to stimulate the hepatic and extra-hepatic synthesis and release of PAI-1 [49, 50], our study confirms, in line with another report, that insulin resistance-driven PAI-1 elevation in MASLD is independently mediated by liver…”
Anthocyanins in Staple Crops
Petroni, K., Pilu, R., & Tonelli, C. (2015) · Springer eBooks · doi:10.1007/978-1-4939-2356-4_13 · Cited by 4
Insulin resistance and vascular disease
Maritz, F. J. (2004) · Journal of Endocrinology Metabolism and Diabetes of South Africa · doi:10.1080/16089677.2004.11073590 · Cited by 4
Sulodexide and Alzheimer’s Disease: A Preliminary Prospective Study
Lasierra-Cirujeda, J., Pascual-Salcedo, M. J. A., & Aza‐Pascual‐Salcedo, M. (2016) · World Journal of Cardiovascular Diseases · doi:10.4236/wjcd.2016.62007 · Cited by 4
“0230450100 [172] Juhan-Vague, I.”
Three generations of epigenetic clocks in mediating the adverse effect of smoking on metabolic health
Yeh, C.-Y., & Lin, W. (2025) · Epigenomics · doi:10.1080/17501911.2025.2494497 · Cited by 3
“Elevated plasminogen activator inhibitor 1 (PAI1) levels are a leading indicator of insulin resistance and MetS [31].”
PAI ‐1 gain‐of‐function genotype, factors increasing PAI ‐1 levels, and airway obstruction: The GALA II Cohort
Sherenian, M. G., Cho, S., Levin, A. M., Min, J., Oh, S. S., Hu, D., Galanter, J., Sen, Ś., Huntsman, S., Eng, C. S., et al. (2017) · Clinical & Experimental Allergy · doi:10.1111/cea.12958 · Cited by 3
Recent updates on the influence of iron and magnesium on vascular, renal, and adipose inflammation and possible consequences for hypertension
Connolly, B. J., & Saxton, S. N. (2024) · Journal of Hypertension · doi:10.1097/hjh.0000000000003829 · Cited by 3
“These alterations are driven by inflammation and the resulting deterioration of endothelial function, resulting in hypertension [129,130].”
Background
Protective effect of serum carotenoids on mortality among metabolic syndrome patients: attenuated by lipid-lowering drugs
Li, C., Liang, Y., Lu, Q., Lin, Y., Wen, S., Luo, X., Huang, S., Zhong, X. B., Xu, Z., & Wang, F. (2025) · Nutrition Journal · doi:10.1186/s12937-025-01092-x · Cited by 3
“This also results in increased reactive oxygen species (ROS), leading to oxidative stress and inflammation [54–56].”
Assessing plasminogen activation potential with global fibrinolytic assays
Urano, T., & Suzuki, Y. (2019) · Research and Practice in Thrombosis and Haemostasis · doi:10.1002/rth2.12293 · Cited by 3
Obesity and metabolic syndrome
Gopalan, C., & Kirk, E. P. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-823421-1.00001-9 · Cited by 3
Markers of fibrinolysis as predictors for maintenance of sinus rhythm after electrical cardioversion
Andersson, J. S. O., Almroth, H., Höglund, N., Jensen, S. M., Tornvall, P., Englund, A., Rosenqvist, M., & Boman, K. (2011) · Thrombosis Research · doi:10.1016/j.thromres.2010.06.002 · Cited by 3
“The prognostic value of PAI-1 levels often disappears after adjustment for metabolic factors as PAI-1 is elevated in the insulin resistance syndrome [20].”
Background
The fibrinolytic enzyme system : New markers of potential interest in cardiovascular disease
Nordenhem, A. (2005) · Figshare · Cited by 3
Association between life’s crucial 9 and sarcopenia: estimated glucose disposal rate as a key mediator
Tang, X., Li, B., Li, D., & Wang, Y. (2025) · Frontiers in Nutrition · doi:10.3389/fnut.2025.1619613 · Cited by 2
Hepatokines modulation in obesity: which exercise training model is better in men with obesity?
Ataeinosrat, A., Abednatanzi, H., Hajesfandiari, S., Nasser, M. N. A., Dara, M. M., Farzanegi, P., Nahand, M. S., Almaqhawi, A., Karimi, N., Bagherzadeh-Rahmani, B., et al. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1560453 · Cited by 3
Influence of Donor Age, Donor Body Mass Index, and Harvesting Site on Cell Preparations from Human Adipose Tissue
Hahn, O., Ficht, P., Bergmann‐Ewert, W., Meyer, J., Wolff, A., & Peters, K. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27031351 · Cited by 2
Metabolic, genetic and immunological features of relatives of type 1 diabetes patients with elevated insulin resistance
Codazzi, V., Salvatore, V., Ragogna, F., Marzinotto, I., Anselmo, A., Baldoni, N., Pastore, M. R., Martinenghi, S., Stabilini, A., Bosi, E., et al. (2024) · Journal of Endocrinological Investigation · doi:10.1007/s40618-024-02497-x · Cited by 3
“Additionally, elevated serum levels of PAI-1, an early inflammatory marker [ 37], were found to be influenced by BMIp as also reported by Koca et al. [38 , 39 ]; while active amylin, a peptide secreted together with insulin by pancreatic β cells [40 ], correlated with HOMA-IR, confirming previous…”
Genetics of Obesity and Diabetes
Sanoudou, D., & Mantzoros, C. S. (2006) · Humana Press eBooks · doi:10.1007/978-1-59259-985-1_3 · Cited by 2
Tissu adipeux viscéral et thrombose
Juhan-Vague, I., & Alessi, M. (2008) · Archives des Maladies du Coeur et des Vaisseaux - Pratique · doi:10.1016/s1261-694x(08)71407-x · Cited by 2
Self-citation
Aging: Thromboembolic Disease, Metabolic Syndrome, Type 2 Diabetes Mellitus, and Alzheimer’s Disease
Lasierra-Cirujeda, J., Pascual-Salcedo, M. J. A., Lasierra-Ibañez, A., AZA, C. L., & Aza‐Pascual‐Salcedo, M. (2016) · Journal of Biosciences and Medicines · doi:10.4236/jbm.2016.45001 · Cited by 3
“IR is associated to an increase of development of cardiovascular illnesses [159]-[161] strongly related to a decreased fibrinolytic activity due to a marked increase of PAI-1 [22] [38] [128] [162]-[167].”
Background
Revisión sistemática de los biomarcadores y su asociación con el Síndrome Metabólico en México
Solis, A. L. G. (2018) · Hospital medicine and clinical management · doi:10.24875/hmcm.18000091 · Cited by 2
Simulated in vitro hypoxic conditions from psoriatic arthritis cartilage change plasminogen activating system urokinase and serpine functionality. Reversal of antiapoptotic protection suggests common homeostatic buffering
Nohawica, M., Nowak, A., Adamska, K., & Wyganowska‐Świątkowska, M. (2022) · Advances in Dermatology and Allergology · doi:10.5114/ada.2022.113405 · Cited by 2
“It is elevated during inflammatory processes such as diabetes [101], and reports show that it has an inhibitory function during wound healing [102].”
Background
Fibrinolytic factors in relation to anthropometry and incident type 2 diabetes.
Hernestål-Boman, J. (2014) · Cited by 2
Relationship between hepatic enzymes and insulin resistance syndrome markers in HIV with lipodystrophy
Larrañaga, G. F. D., Wingeyer, S. D. P., & Benetucci, J. A. (2004) · Hepatology · doi:10.1002/hep.20489 · Cited by 2
Mechanisms and effects of low plasminogen activator inhibitor type 1 activity
Ågren, A. (2008) · Figshare · Cited by 2
Determinación de factores trombofílicos en pacientes con trombosis venosas retinianas
Leonidas Traipe, C., Guillermo Conté, L., S, F. J. C., Santiago Ibáñez, L., Patricio Meza, R., Basilio Rojas, U., Cuneo, M., V, & Verdaguer, J. (2005) · Revista médica de Chile · doi:10.4067/s0034-98872005000200003 · Cited by 2
“El grupo sin etiología trombofílica asociada al cuadro trombótico (esto es, los 38 pacientes restantes), tenía un promedio de edad de 62 años (22-86) y 76,5% presentaba una oclusión de vena central.”
Background
Reduced Expression of Urokinase Plasminogen Activator in Brown Adipose Tissue of Obese Mouse Models
Wu, C., Chang, L.-C., Cheng, C., Fang, T., Lin, Y., Pei, D., & Chen, J.-S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22073407 · Cited by 2
“Although some studies showed PAI-1 to be associated with adipocyte differentiation and regulating recruitment of inflammatory cells within adipose tissue [27], we found that serum PAI-1 levels of CD and HFD mice did not differ significantly in C57BL/6J mice.”
Background
Metabolic Changes Induced by Bariatric Surgery May be Mediated by PAI-1 and PCSK9 Crosstalk
Castro‐Leyva, V., Apolinar, L. M., Basurto-Acevedo, N. E., Basurto, L., González-Chávez, A., Ruiz-Gastélum, E., & Murillo, C. M. (2024) · Archives of Medical Research · doi:10.1016/j.arcmed.2024.103032 · Cited by 1
Microbiome and Metabolic Biomarkers in Metabolic Syndrome
Gupta, R., Lekshmi, N., Sikri, K., Bhalla, M., & Vashist, A. (2025) · Springer eBooks · doi:10.1007/978-981-96-6246-3_12 · Cited by 1
Targeting mitochondrial biogenesis: Chandraprabha Vati in the management of metabolic syndrome
Dongre, P., & Majumdar, A. S. (2025) · Phytomedicine Plus · doi:10.1016/j.phyplu.2025.100841 · Cited by 1
Clinical uses of inorganic and organic nanoparticles in metabolic syndromes
Debnath, S., Kalyankumarraju, M., Dixit, A. K., & Babu, G. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-28942-2.00012-0 · Cited by 1
Dysregulation of Endothelial cell markers in polycystic ovary syndrome
Borde, P., Niinuma, S. A., Habib, H., Takemoto, A. S.-N., Nandakumar, M., Sathyapalan, T., Butler, A. E., & Atkin, S. L. (2026) · Scientific Reports · doi:10.1038/s41598-026-40533-3 · Cited by 2
“Specifically, there may be a potential association between elevation in PAI-1 levels and impaired fibrinolysis, which leads to the suppression of plasmin formation 56 .”
Pathophysiology and pharmacotherapy of cardiovascular complications in metabolic syndrome
Dhalla, N. S., Patel, C. A., Beladiya, J., Mehta, A. A., & Gandhi, T. R. (2026) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2026.04.007 · Cited by 1
Molecular Aspects of Obesity and Insulin Resistance in Metabolic Syndrome and Neurological Disorders
Farooqui, A. A. (2013) · Springer eBooks · doi:10.1007/978-1-4614-7318-3_5 · Cited by 1
Studies on the Role of Vitronectin and Plasminogen-Activator Inhibitor-1 Complexes Beyond Inhibiting Proteases: Binding to the Extracellular Matrix, Cell Interactions and Pathogenesis
Goswami, S. (2010) · Cited by 1
Cardiovascular Risk Assessment in Diabetes and Chronic Kidney Diseases: A New Insight and Emerging Strategies
Reza, A. (2012) · InTech eBooks · doi:10.5772/31494
“platelet function through nitric oxide, a pathway that is impaired in DM patients [217].”
Background
Resolution of Budd???Chiari syndrome due to activation of endogenous fibrinolysis that may be induced by weight reduction
abovi, M. O., & ek, T. K. E. (2005) · Blood Coagulation & Fibrinolysis · doi:10.1097/00001721-200501000-00008 · Cited by 1
Low PAI‐1 activity in relation to inflammatory parameters, insulin profile and body mass index
Ågren, A., Wiman, B., & Schulman, S. (2008) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2008.01999.x · Cited by 1
PAI-1 and lifestyle-related illnesses
Yamamoto, K. (2008) · Japanese Journal of Thrombosis and Hemostasis · doi:10.2491/jjsth.19.55 · Cited by 1
Obezite ve periodontitis
Köse, O., Çanakçı, V., Arabacı, T., & Sağlam, E. (2012) · Dspace Repository (Marmara Üniversitesi) · Cited by 1
Plasminogen Activator Inhibitor-1, Body Fat and Insulin Action in Aging Women.
McMillin, S. L., & Ryan, A. S. (2014) · PubMed · Cited by 1
Oral Contraceptive Use in Obese Adolescents: A Cautionary Tale
Warad, D., Chattha, A. J., & Rodriguez, V. (2021) · Journal of Pediatric Hematology/Oncology · doi:10.1097/mph.0000000000002053 · Cited by 1
“Several hemostatic abnormalities have been observed in obesity such as altered ﬁbrinolysis, increased plasminogen activator inhibitor (PAI-1), increased platelet aggregability through elevations of von Willebrand factor and higher levels of ﬁbrinogen, factors VII and VIII (8-10).”
Hemostatic abnormalities associated with obesity and the metabolic syndrome
Juhan-Vague, I., & Alessi, M. (2005) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2005.01281.x · Cited by 1
Self-citation
Effect of Weight Reduction on Inflammatory Mediators in Patients with and without Metabolic Syndrome
Hassanin, H. M., Khali, U. A., Sediq, A., & Elshabrawy, A. M. (2022) · The Egyptian Journal of Hospital Medicine · doi:10.21608/ejhm.2022.256616 · Cited by 1
“Insulin resistance also increases serum viscosity, induces a hypercoagulable state, and produces proinflammatory cytokines, which are released from the adipose tissue promoting the increased risk of cardiovascular disease (CVD) (7).”
Background
ADIPOCYTOKINES IN DEVELOPMENT INSULIN RESISTANCE IN OBESITY
Yarmysh, N. V., Кравченко, Н. А., & Voitenko, E. I. (2010) · PROBLEMS OF ENDOCRINE PATHOLOGY · doi:10.21856/j-pep.2010.3.17 · Cited by 1
White Adipose Tissue: Beyond Fat Storage
Imam, S. K. (2015) · Springer eBooks · doi:10.1007/978-3-319-19821-7_1 · Cited by 1
Gender difference in plasminogen activator inhibitor-1 activity in patients with type 2 diabetes with and without albuminuria, a matched case-control study
Imani, M., Rabizadeh, S., Nakhjavani, M., Hashemi, P., Pezeshki, S., Hizomi, R., Esteghamati, A., & Mirmiranpour, H. (2019) · Functional Foods in Health and Disease · doi:10.31989/ffhd.v9i7.595 · Cited by 1
“In addition, increasing evidence shows that obesity increases PAI-1 production in ectopic fat tissue, while weight loss decreases the production [25, 26].”
Background
Influences and Complications
Amend, G., Baird, A. D., Baradaran, N., Bele, U., Breyer, B. N., Cito, G., Drake, M. J., Henderson, E. J., Joinson, C. J., Rivas, J. G., et al. (2019) · Springer eBooks · doi:10.1007/978-3-030-27747-5_7 · Cited by 1
Combined but not single treatment with ethinylestradiol/levonorgestrel and spironolactone reduces plasminogen activator inhibitor-1 in insulin-resistant ovariectomised rats
Aremu, A. O., Dibia, C., Olufemi, S. A., & Aderemi, O. L. (2019) · Journal of the Renin-Angiotensin-Aldosterone System · doi:10.1177/1470320319895933 · Cited by 2
40 Venous Thrombosis and Pulmonary Embolism in the Bariatric Surgery Patient
Grover, B. T., & Kothari, S. N. (2014) · Springer eBooks · doi:10.1007/978-1-4939-1637-5_40 · Cited by 1
Adipokines, Inflammation, and Obesity
Clément, K. (2010) · Wiley eBooks · doi:10.1002/9783527629527.ch14 · Cited by 1

Authors: Juhan-Vague, I., Alessi, M.-C., Mavri, A., & Morange, P. E.
Affiliations: Inserm (FR)
Corresponding author: Juhan-Vague, I.
ORCID: Alessi, M-C.
Mavri, A.
Morange, P.E.
Venue: Journal of Thrombosis and Haemostasis
Publisher: Elsevier BV
Published: 2003-07
Volume: 1
Issue: 7
Pages: 1575-1579
ISSN: 1538-7836 (ISSN-L)
DOI: 10.1046/j.1538-7836.2003.00279.x
OpenAlex: W2042742088
Cited by: 371
References: 95
Citations by year: 2026: 9 · 2025: 13 · 2024: 13 · 2023: 8 · 2022: 14 · 2021: 6 · 2020: 11 · 2019: 14 · 2018: 10 · 2017: 17 · 2016: 9 · 2015: 19 · 2014: 14 · 2013: 11 · 2012: 13
FWCI: 4.40
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/legal/tdmrep-license (tdm)
www.elsevier.com/open-access/userlicense/1.0/ (vor, 7104 d)
Locations: Journal of Thrombosis and Haemostasis (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Hematology › Blood Coagulation and Thrombosis Mechanisms
Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Protease and Inhibitor Mechanisms
Keywords: plasminogen activator inhibitor-1, metabolic syndrome, inflammation, obesity, adipose tissue, inflammatory cytokines, impaired fibrinolysis, atherothrombosis, vascular risk, PAI-1 inhibitors, atherosclerosis
MeSH terms: Animals, Heart Diseases, Humans, Insulin Resistance, Obesity, Risk, Plasminogen Activator Inhibitor 1

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Plasminogen activator inhibitor-1, inflammation, obesity, insulin resistance and vascular risk

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks